Replies to post #197801 on Biotech Values

[DewDiligence]

BMY/ABBV—Empliciti failed to show statsig-better PFS when added to Revlimid/dexamethasone in first-line MM in phase-3 ELOQUENT-1 study:

https://finance.yahoo.com/news/bristol-myers-squibb-reports-primary-105900628.html

PFS was the primary endpoint. HR and other data have not yet been disclosed.